Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.78 |
| ▸ | ITGA2B | P08514 | 20/20 | 0.78 |
| ▸ | F2R | P25116 | 12/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6942734 | 1.00 | ITGB3 (0.78) | ITGB3ITGA2BF2R | |
| SCHEMBL6937894 | 1.00 | ITGB3 (0.78) | ITGB3ITGA2BF2R | |
| SCHEMBL6939580 | 1.00 | ITGB3 (0.78) | ITGB3ITGA2BF2R | |
| SCHEMBL7815623 | 1.00 | ITGB3 (0.78) | ITGB3ITGA2BF2R | |
| Hydrochloric Acid SCHEMBL7500164 | 0.99 | ITGB3 (0.77) | ITGB3ITGA2BF2R | |
| Water SCHEMBL6938264 | 0.99 | ITGB3 (0.77) | ITGB3ITGA2BF2R | |
| Hydrochloric Acid SCHEMBL7500996 | 0.99 | ITGB3 (0.77) | ITGB3ITGA2BF2R | |
| SCHEMBL6539830 | 0.93 | ITGB3 (0.79) | ITGB3ITGA2BF2R | |
| SCHEMBL6538736 | 0.93 | ITGB3 (0.79) | ITGB3ITGA2BF2R | |
| Hydrochloric Acid SCHEMBL7502038 | 0.92 | ITGB3 (0.78) | ITGB3ITGA2BF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114488-A1 | New processes for producing beta-alanine derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-19 | — | — | US | disclosed |
| US-6538007-B1 | Hydrates and method of antogonizing glycoprotein IIb/IIIa activity using these compounds is also disclosed. antagonist, inhibitor of blood platelets aggregation and inhibitor of the binding of fibrinogen to blood platelets. | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114488-A1 | New processes for producing beta-alanine derivatives | BCAT1, BCAT2, AGXT | ITGB3 3266/4885ITGA2B 3019/4885F2R 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.